Affiliation:
1. N.N. Blokhin National Medical Research Center of Oncology
2. N.N. Blokhin National Medical Research Center of Oncology;
Burnasyan Federal Medical Biophysical Center;
Kurnakov Institute of General and Inorganic Chemistry
3. N.N. Blokhin National Medical Research Center of Oncology;
Kurnakov Institute of General and Inorganic Chemistry
Abstract
The object of the study was to analyze radionuclide detection techniques for in vivo animal imaging. Material and Methods. A total of 49 publications available from Scopus, Web of Science, Google Scholar eLIBRARY and Pubmed and published between 2013 and 2019 were reviewed. Results. The nuclear medicine techniques, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT) are the most suitable imaging modalities for in vivo animal imaging. Besides traditional radiopharmaceuticals, such as [18F]-FDG and [99mTc]-MDP, the new radiolabeled tracers, such as [99mTc]-3PRGD2, [ 99mTc]-HisoDGR targeted to integrin, [18F]- tetrafluoroborate, labeled antibodies and others have been used for the noninvasive detection of tumors and for monitoring their response to treatment in mice and rats. 111In and 89Zr –labeled monoclonal antibodies are used to evaluate the expression level of many receptors such as EGFR, HER-2 and others in different tumors. PET imaging has demonstrated a good efficacy in tumor hypoxia imaging with [64Cu]-ATSM, [18F]-FMISO. PET and SPECT can also be used for early evaluation of anticancer therapy response. Nuclear imaging techniques may assist in the vivo assessment of DNA damage (doubleand single-strand brakes) as well as apoptosis intensity in tumor and normal tissues. [99mTc]- duramycin is the most commonly used tracer for imaging of apoptosis. Changes in tumor cell proliferation in response to anticancer therapy can be assessed by PET imaging with [18F]-FLT. Conclusion. Nuclear medicine offers a unique means to study cancer biology in vivo and to optimize cancer therapy.
Publisher
Tomsk Cancer Research Institute
Reference51 articles.
1. Stukalov Y.V., Grigorieva E.Y., Smirnova A.V., Lipengolts A.A., Kubasova I.Y., Pozdniakova N.V., Lukashina M.I. Experimental study of dendrimer-based nanoparticles with RGD-peptide for anticancer radionuclide therapy. Bulletin of RSMU. 2018; 7(6): 113–9. doi: 10.24075/brsmu.2018.089
2. Sheino I.N., Izhevskij P.V., Lipengolts A.A., Kulakov V.N., Wagner A.A., Sukhikh E.S., Varlachev V.A. Development of binary technologies of radiotherapy of malignant neoplasms: condition and problems. Bulletin of Siberian Medicine. 2017; 16(3): 192–209. (in Russian). doi: 10.20538/1682-0363-2017-3-192.
3. Kulakov V.N., Lipengol’ts A.A., Grigor’eva E.Y., Shimanovskii N.L. Pharmaceuticals for binary radiotherapy and their use for treatment of malignancies. Pharm Chem J. 2016; 50(6): 388–93. doi: 10.1007/s11094-016-1457-3.
4. Lipengolts A.A., Cherepanov A.A., Kulakov V.N., Grigorieva E.Y., Sheino I.N., Klimanov V.A. Antitumor efficacy of extracellular complexes with gadolinium in Binary radiotherapy. Appl Radiat Isot. 2015; 106: 233–6. doi: 10.1016/j.apradiso.2015.07.051.
5. Lipengolts A.A., Vorobyeva E.S., Cherepanov A.A., Abakumov M.A., Abakumova T.O., Smirnova A.V., Finogenova Yu.A., Grigorieva E.Yu., Sheino I.N., Kulakov V.N. Evaluation of absorbed dose distribution in melanoma B16F10 during contrast enhanced radiotherapy with intratumoral administration of dose-enhancing agent. Bulletin of Russian State Medical University. 2018; (5): 70–5. (in Russian). doi: 10.24075/vrgmu.2018.062.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献